|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:atccode
|
J04 A A01
|
|
gptkbp:brand
|
Laniazid
|
|
gptkbp:can_be_combined_with
|
gptkb:ethambutol
gptkb:pyrazinamide
gptkb:rifampicin
|
|
gptkbp:casnumber
|
54-85-3
|
|
gptkbp:chemical_formula
|
C6 H6 N4 O
|
|
gptkbp:contraindication
|
acute liver disease
history of liver disease
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discovered_by
|
gptkb:1952
|
|
gptkbp:dosage_form
|
gptkb:tablet
injectable
|
|
gptkbp:duration
|
6 to 9 months
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
isoniazid
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:beer
|
|
gptkbp:is_monitored_by
|
liver function tests
neurological status
|
|
gptkbp:is_used_for
|
tuberculosis
|
|
gptkbp:mechanism_of_action
|
inhibits mycolic acid synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
essential medicines
|
|
gptkbp:pharmacokinetics
|
bioavailability 90%
half-life 1-4 hours
protein binding 10% to 20%
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:anemia
nausea
fever
vomiting
seizures
rash
peripheral neuropathy
hepatotoxicity
|
|
gptkbp:synergistic_effect
|
gptkb:ethambutol
gptkb:pyrazinamide
gptkb:rifampicin
|
|
gptkbp:treatment
|
drug-resistant tuberculosis
|
|
gptkbp:water_resistance
|
decreased drug uptake
mutation in kat G gene
overexpression of inh A gene
|
|
gptkbp:bfsParent
|
gptkb:rifampicin
|
|
gptkbp:bfsLayer
|
4
|